Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

Kevin M. McKown; Laura D. Carbone; Stanley B. Kaplan; Jacob A. Aelion; Kristine M. Lohr; Michael A. Cremer; Juan Bustillo; Miguel Gonzalez; Gurjit Kaeley; Elaine L. Steere; Grant W. Somes; Linda K. Myers; Jerome M. Seyer; Andrew H. Kang; Arnold E. Postlethwaite

doi:10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

Kevin M. McKown, Laura D. Carbone, Stanley B. Kaplan, Jacob A. Aelion, Kristine M. Lohr, Michael A. Cremer, Juan Bustillo, Miguel Gonzalez, Gurjit Kaeley, Elaine L. Steere, Grant W. Somes, Linda K. Myers, Jerome M. Seyer, Andrew H. Kang, Arnold E. Postlethwaite

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

Original language	English (US)
Pages (from-to)	1204-1208
Number of pages	5
Journal	Arthritis and Rheumatism
Volume	42
Issue number	6
DOIs	https://doi.org/10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U
State	Published - Jun 1999
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology
Pharmacology (medical)

Access to Document

10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

Cite this

McKown, K. M., Carbone, L. D., Kaplan, S. B., Aelion, J. A., Lohr, K. M., Cremer, M. A., Bustillo, J., Gonzalez, M., Kaeley, G., Steere, E. L., Somes, G. W., Myers, L. K., Seyer, J. M., Kang, A. H., & Postlethwaite, A. E. (1999). Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis and Rheumatism, 42(6), 1204-1208. https://doi.org/10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

McKown, KM, Carbone, LD, Kaplan, SB, Aelion, JA, Lohr, KM, Cremer, MA, Bustillo, J, Gonzalez, M, Kaeley, G, Steere, EL, Somes, GW, Myers, LK, Seyer, JM, Kang, AH & Postlethwaite, AE 1999, 'Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis', Arthritis and Rheumatism, vol. 42, no. 6, pp. 1204-1208. https://doi.org/10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

@article{684f6cceca9c4039895d129bdf62e1eb,

title = "Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis",

abstract = "Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.",

author = "McKown, {Kevin M.} and Carbone, {Laura D.} and Kaplan, {Stanley B.} and Aelion, {Jacob A.} and Lohr, {Kristine M.} and Cremer, {Michael A.} and Juan Bustillo and Miguel Gonzalez and Gurjit Kaeley and Steere, {Elaine L.} and Somes, {Grant W.} and Myers, {Linda K.} and Seyer, {Jerome M.} and Kang, {Andrew H.} and Postlethwaite, {Arnold E.}",

year = "1999",

month = jun,

doi = "10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U",

language = "English (US)",

volume = "42",

pages = "1204--1208",

journal = "Arthritis and Rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

AU - McKown, Kevin M.

AU - Carbone, Laura D.

AU - Kaplan, Stanley B.

AU - Aelion, Jacob A.

AU - Lohr, Kristine M.

AU - Cremer, Michael A.

AU - Bustillo, Juan

AU - Gonzalez, Miguel

AU - Kaeley, Gurjit

AU - Steere, Elaine L.

AU - Somes, Grant W.

AU - Myers, Linda K.

AU - Seyer, Jerome M.

AU - Kang, Andrew H.

AU - Postlethwaite, Arnold E.

PY - 1999/6

Y1 - 1999/6

N2 - Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

AB - Objective. To investigate the efficacy of oral type II collagen (CII) in the treatment of rheumatoid arthritis (RA), when added to existing therapy. Methods. Patients with active RA (n = 190) were randomized into a 6-month, double-blind, placebocontrolled trial. Patients continued to take their current arthritis medications. Patients received either placebo or bovine CII, 0.1 mg/day for 1 month, then 0.5 mg/day for 5 months. Results. There were no significant differences between the baseline characteristics of either group. The primary response parameter was the American College of Rheumatology (ACR) preliminary definition of improvement in RA (ACR 20). There was no statistically significant difference in the ACR 20 after 6 months (20.0% of placebo patients; 16.84% of bovine CII patients). There were significant differences in several clinical variables after treatment, all favoring the placebo group. Conclusion. Oral solubilized bovine CII, added to existing therapy, did not improve disease activity in patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=0033000532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033000532&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

DO - 10.1002/1529-0131(199906)42:6<1204::AID-ANR17>3.0.CO;2-U

M3 - Article

C2 - 10366113

AN - SCOPUS:0033000532

SN - 0004-3591

VL - 42

SP - 1204

EP - 1208

JO - Arthritis and Rheumatism

JF - Arthritis and Rheumatism

IS - 6

ER -

Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this